PRE trades 166.6% below Wall Street's consensus target of $42.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PRE achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Prenetics Global Limited (PRE) has a Wall Street consensus price target of $42.50, based on estimates from 2 covering analysts. With the stock currently trading at $15.94, this represents a potential upside of +166.6%. The company has a market capitalization of $271M.
Analyst price targets range from a low of $35.00 to a high of $54.00, representing a 45% spread in expectations. The median target of $40.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PRE trades at a trailing P/E of -4.1x. Analysts expect EPS to grow +10.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NTRANatera, Inc. | $44.5B | $310.67 | $393.16 | +26.6% | Buy | — | 28 |
 CSTLCastle Biosciences, Inc. | $986M | $32.52 | $38.75 | +19.2% | Buy | — | 11 |
 QDELQuidelOrtho Corporation | $730M | $10.70 | $12.25 | +14.5% | Hold | 13.9x | 15 |
 AHCOAdaptHealth Corp. | $997M | $7.33 | $9.83 | +34.1% | Buy | — | 12 |
 HIMSHims & Hers Health, Inc. | $5.8B | $26.00 | $32.17 | +23.7% | Hold | — | 20 |
 MYRGMYR Group Inc. | $4.1B | $262.91 | $391.33 | +48.8% | Buy | 20.3x | 22 |
 TMOThermo Fisher Scientific Inc. | $258.2B | $694.76 | $694.27 | -0.1% | Buy | 27.5x | 43 |
 DHRDanaher Corporation | $161.9B | $230.25 | $238.77 | +3.7% | Buy | 26.8x | 43 |
 IQVIQVIA Holdings Inc. | $44.7B | $271.83 | $289.91 | +6.7% | Buy | 21.0x | 45 |
 LHLabcorp Holdings Inc. | $30.1B | $366.57 | $389.89 | +6.4% | Buy | 19.8x | 35 |
Quick answers to the most common questions about buying PRE stock.
The consensus Wall Street price target for PRE is $42.5, representing 166.6% upside from the current price of $15.94. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PRE has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $42.5 implies 166.6% upside from current levels.
PRE's current price is $15.94 with a consensus target of $42.5 (166.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $54 for PRE, while the most conservative target is $35. The consensus of $42.5 represents the median expectation. These targets typically reflect 12-month expectations.
PRE is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PRE stock forecast based on 2 Wall Street analysts shows a consensus price target of $42.5, with estimates ranging from $35 (bear case) to $54 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PRE, with a "Buy" consensus rating and $42.5 price target (166.6% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PRE analyst price targets range from $35 to $54, a 45% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $42.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.